medicines available to health care
professionals and patients
largest player worldwide
and 2nd in Europe
patients worldwide treated with
a Servier medicine for a condition affecting
the heart or blood vessels
Cardiovascular diseases are the leading cause of mortality in the world and are responsible for 31% of deaths1 every year. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired recognized expertise.
More than 17 million patients worldwide are being treated with a Servier medicine for a condition affecting the heart or blood vessels. Servier continues to innovate in the field of heart failure: Omecamtiv mecarbil, a selective cardiac myosin activator developed in close collaboration with Amgen and Cytokinetics, is in phase III clinical evaluation.
Servier also focuses its innovation efforts on developing Single Pill Combinations (SPC). By simplifying treatment, these SPCs increase treatment compliance.